Drug data lifts JNJ
JNJ is climbing moderately on positive long-term clinical data for its plaque psoriasis drug Icotyde, with steady volume and low volatility suggesting a calm, orderly bid rather than a speculative rush.
Sources: https://www.prnewswire.com/news-releases/new-johnson--johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment
Previous verdicts for JNJ
- AI Search: JNJ Rises Modestly on New Device and Rheumatology Data — 2026-10-22
- JNJ device launch — 2026-10-20
- AI Search: JNJ Sells Off Sharply Despite Q3 Beat and Raised Guidance — 2026-10-13
- AI Search: JNJ edges higher as ICOTYDE psoriasis data outweighs guidance cut — 2026-10-07
- JNJ Drifts Lower Quietly — 2026-10-01
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works